Search results for: hip OA

The ACR, ARHP Develop National Research Agenda for 2016–2020

From the College | April 15, 2016

Since 2005, the ACR’s Committee on Research has been responsible for advancing the research goals of the organization and providing leadership in research and research training in rheumatology via the ACR’s Research Agenda. The ACR Research Agenda is designed to address critical areas of research in rheumatic diseases, including the need for new technology, new…

Research Provides Insight into Impact of Microbiome on Health, Rheumatic Disease

Neha Ohri, MD, & Kristine A. Kuhn, MD, PhD | April 15, 2016

The microbiome comprises diverse microbial flora, including bacteria, viruses and fungi, that live on mucosal surfaces, predominantly the skin and digestive tract. Microbes evolved billions of years prior to the development of modern Homo sapiens 200,000 years ago; we have always existed with their ubiquitous presence. Despite this, the first microbe was not visualized until…

Opinion: Politics Should Not Trump Science in Medicine

John A. Goldman, MD | April 15, 2016

I tell my patients there are three types of science: 1) investigative science, which sometimes gets it right; 2) science in the courtroom, which is junk science; and 3) science in Washington, D.C., which is political science. Our decisions are based on art and science; our patients’ medications are brought to market based on science….

Biosimilars Debate Heats up over Cost Savings, Safety Concerns

Susan Bernstein | April 15, 2016

After years of speculation about potential cost savings and debates on safety, biosimilars are about to step onto the stage of rheumatic disease treatment. On Feb. 9, the Arthritis Advisory Committee of the U.S. Food and Drug Administration (FDA) met in Washington, D.C., and recommended the approval of CT-P13, a proposed biosimilar to infliximab (Remicade),…

Diagnostic Imaging in Patient with Chronic Left Ankle Pain: Findings

Cianna Leatherwood, MD, & Derrick J. Todd, MD, PhD | April 15, 2016

Radiographic imaging showed circumferential soft tissue swelling of the ankle with a soft-tissue density seen in the tibiotalar and posterior subtalar joints, as well as a large, lobulated effusion. MRI of the left ankle shows cystic changes within the talus and first cuneiform bones, as well as a lobulated abnormal soft tissue density with low…

Tips for Selecting Best Job Candidates to Fill Positions, Avoid Turnover

Karen Appold | April 14, 2016

As much as 80% of employee turnover can be attributed to bad hiring decisions, the Harvard Business Review reported.1 And turnover costs are high—one report estimated them to be 100–300% of the base salary of a replaced employee (with 150% commonly cited).2 Given this, the importance of hiring the right employees can’t be underestimated. So…

2015 ACR/ARHP Annual Meeting: Cellular Triggers in Inflammatory Disease

Susan Bernstein | April 14, 2016

SAN FRANCISCO—What factors help determine whether or not inflammation resolves, leading to healing, or becomes chronic, leading to disease and tissue destruction? A number of important cells, including toll-like receptors, mast cells, anti-citrullinated protein antibodies, complement and interferon, all play their own role in this process. By understanding how they act in innate and adaptive…

Ethics Forum: Pediatric Vaccination Refusals Raise Challenges for Physicians

Emily von Scheven, MD, MAS | April 13, 2016

The boy who could not walk: S.L. is a previously healthy 10-year-old boy who has not walked for three months. Physical examination reveals swollen wrists, knees, ankles and several toes. There is reduced hip range of motion and flexion contractures of both knees. He can stand with assistance, but is unable to take a single…

Etanercept Submitted to FDA for Approval to Treat Pediatric Plaque Psoriasis; Boehringer Ingelheim & AbbVie to Collaborate; Low Doses of Gerilimzumab Promising for RA

Michele B. Kaufman, PharmD, BCGP | April 13, 2016

The FDA has received an application to expand the use of etanercept to treat plaque psoriasis in pediatric patients. Boehringer Ingelheim and AbbVie have announced a collaborative partnership to develop treatments for multiple autoimmune diseases. And gerilimzumab may prove safe and effective for treating inflammatory diseases at very low doses…

Abaloparatide Effective for Osteoporosis & XmAb5871 Studied to Treat SLE

Michele B. Kaufman, PharmD, BCGP | March 30, 2016

Abaloparatide has completed clinical trials, which showed the treatment to be safe and effective in reducing fracture rates in postmenopausal women with osteoporosis. Also, XmAb5871 is being studied to treat systemic lupus erythematosus and doesn’t destroy B cells…